Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial
January 11, 2023 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals Reports Data Showing Novel Drug Candidate is First-in-class B55α/PP2A Activator
October 13, 2022 07:00 ET
|
Emerald Health Pharmaceuticals
Data published in peer-reviewed journal confirms novel mechanism of action SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a...
Emerald Health Pharmaceuticals Completes Enrollment of First Two Cohorts of Phase II Systemic Sclerosis Trial
October 07, 2022 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to...
Emerald Health Pharmaceuticals Reaches Settlement with U.S. Securities and Exchange Commission
October 03, 2022 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Further to its news release on July 11, 2022, Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”) has reached a settlement (the...
Emerald Health Pharmaceuticals Announces Resignation of CEO and CFO
July 11, 2022 00:41 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, July 11, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals Strengthens Global Patent Portfolio with New International Patents
April 05, 2022 16:03 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, April 05, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals Receives IND Clearance to Begin Phase 2 Clinical Trial of EHP-101 for Relapsing Forms of Multiple Sclerosis
January 11, 2022 09:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals Adds Leading Rheumatologist to Distinguished Systemic Sclerosis Clinical Advisory Board
December 09, 2021 09:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...
Emerald Health Pharmaceuticals’ Novel Drug Candidate Demonstrates Significant Anti-inflammatory and Anti-fibrotic Activity in Multi-organ Fibrosis Preclinical Model
December 02, 2021 13:31 ET
|
Emerald Health Pharmaceuticals
Data published in peer-reviewed journal show ability of EHP-101 to prevent cardiac, renal, pulmonary and dermal fibrosis SAN DIEGO, CA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Emerald Health...
Emerald Health Pharmaceuticals Expands Scientific Advisory Board with the Appointment of Neuroscience Expert Dr. Eduardo Candelario-Jalil
May 24, 2021 11:05 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, May 24, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat...